Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Core Insights - Alterity Therapeutics is set to present data from its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson's Disease and Movement Disorders [1][2] Group 1: Clinical Trial Details - The ATH434-201 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study involving 77 adults, assessing the efficacy, safety, and pharmacokinetics of ATH434 over 12 months [5][6] - ATH434 demonstrated clinically and statistically significant improvements on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, indicating enhanced daily living activities compared to placebo [6] - The trial also showed trends in improved motor performance and increased activity levels in outpatient settings, with both dose levels reducing iron accumulation in affected brain regions [6] Group 2: Presentation Information - The data will be presented in an oral session titled "ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy" by David Stamler, M.D. on October 8, 2025 [3] - Additional poster presentations will cover topics such as the relationship between alpha-synuclein aggregation profiles and disease severity, and differences between clinical and imaging phenotypes in MSA [3] Group 3: About ATH434 - ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins associated with neurodegeneration, showing preclinical efficacy in reducing α-synuclein pathology and preserving neuronal function [4] - The drug has received Fast Track Designation and Orphan Drug Designation from the FDA for the treatment of MSA, indicating its potential significance in addressing this rare disease [4] Group 4: About Multiple System Atrophy - MSA is a rare neurodegenerative disease affecting up to 50,000 individuals in the U.S., characterized by autonomic dysfunction and impaired movement, with no current treatments available to slow disease progression [7]